摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(R)-N-Boc-2-羟甲基吗啉 | 135065-71-3

中文名称
(R)-N-Boc-2-羟甲基吗啉
中文别名
(R)-2-羟甲基吗啉-4-甲酸叔丁酯;(R)-4-叔丁氧羰基-2-羟甲基吗啉;N-叔丁氧羰基-(R)-2-吗啉甲醇;(R)-N-BOC-2-吗啉甲醇;Boc-(R)-2-吗啉甲醇;R-N-Boc-3-羟甲基吗啉;R-2-羟甲基吗啉-4-碳酸数丁酯
英文名称
(R)-2-hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester
英文别名
tert-butyl (2R)-2-(hydroxymethyl)morpholine-4-carboxylate;tert-butyl (R)-2-(hydroxymethyl)morpholine-4-carboxylate;(R)-tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate;(R)-N-Boc-2-hydroxymethyl-morpholine;(2R)-2-(hydroxymethyl)morpholine-4-carboxylic acid tert-butyl ester;(2R,2S)-4-(tert-Butoxycarbonyl)-2-(hydroxymethyl)-morpholine;tert-butyl (2R)-2-(hydroxymethyl)morpholin-4-yl carboxylate;(2R)-tert-butyl 2-(hydroxymethyl)morpholine-4-carboxylate;tert-butyl (2R)-2-(hydroxymethyl)morpholin-4-yl formate;(R)-N-Boc-2-hydroxymethylmorpholine
(R)-N-Boc-2-羟甲基吗啉化学式
CAS
135065-71-3
化学式
C10H19NO4
mdl
MFCD09260605
分子量
217.265
InChiKey
FJYBLMJHXRWDAQ-MRVPVSSYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    59-61 °C
  • 沸点:
    321 °C
  • 密度:
    1.118
  • 闪点:
    148 °C

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.9
  • 拓扑面积:
    59
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    室温

SDS

SDS:3d3a4977fa95957add6d3beb4ab364f3
查看
Material Safety Data Sheet

Section 1. Identification of the substance
(R)-N-Boc-2-hydroxymethylmorpholine
Product Name:
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

Section 3. Composition/information on ingredients.
(R)-N-Boc-2-hydroxymethylmorpholine
Ingredient name:
CAS number: 135065-71-3

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C10H19NO4
Molecular weight: 217.3

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

(R)-N-Boc-2-羟甲基吗啉可作为有机合成中间体和手性医药中间体,主要用于实验室研发过程和化工医药研发过程中手性化合物的合成。此外,它还通过模板筛选用于制备Checkpoint激酶1的抑制剂

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

点击查看最新优质反应信息

文献信息

  • IRAK DEGRADERS AND USES THEREOF
    申请人:Kymera Therapeutics, Inc.
    公开号:US20190192668A1
    公开(公告)日:2019-06-27
    The present invention provides compounds, compositions thereof, and methods of using the same.
    本发明提供了化合物、其组合物以及使用这些化合物的方法。
  • [EN] IMIDAZOPYRIDINE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS IMIDAZOPYRIDINE ET LEURS UTILISATIONS
    申请人:NEOMED INST
    公开号:WO2014117274A1
    公开(公告)日:2014-08-07
    This invention generally relates to substituted imidazopyridine compounds, particularly substituted 4-(imidazo[1,2-a]pyridin-2-yl)benzamide compounds and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processes for making such a compound, and intermediates used in such processes.
    这项发明通常涉及取代咪唑吡啶化合物,特别是取代的4-(咪唑[1,2-a]吡啶-2-基)苯甲酰胺化合物及其盐。这项发明还涉及包含这种化合物的药物组合物和试剂盒,以及这种化合物的用途(包括治疗方法和药物制剂等),制备这种化合物的方法,以及用于这些方法的中间体。
  • [EN] IRAK DEGRADERS AND USES THEREOF<br/>[FR] AGENTS DE DÉGRADATION D'IRAK ET LEURS UTILISATIONS
    申请人:KYMERA THERAPEUTICS INC
    公开号:WO2020264499A1
    公开(公告)日:2020-12-30
    The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.
    本发明提供了化合物、其组合物以及使用这些化合物的方法。这些化合物包括能够结合到IRAK4的IRAK结合基团和诱导降解的基团(DIM)。DIM可以是DTM、一个连接酶结合基团(LBM)或赖酸类似物。这些化合物可以作为IRAK蛋白激酶抑制剂,并应用于IRAK介导的疾病。
  • [EN] NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS<br/>[FR] NOUVEAUX DÉRIVÉS DE PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE UTILISÉS EN TANT QU'INHIBITEURS DE P2X3
    申请人:BAYER AG
    公开号:WO2019081343A1
    公开(公告)日:2019-05-02
    The present invention covers substituted Pyrazolo-pyrrolo-pyrimidine-dione (PPPD) compounds of general formula (I): in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of neurogenic diseases, as a sole agent or in combination with other active ingredients.
    本发明涵盖了一般式(I)的取代吡唑基-吡咯基-嘧啶二酮(PPPD)化合物:其中R1、R2和R3如本文所定义,制备所述化合物的方法,包含所述化合物的药物组合物和配方,以及利用所述化合物制造用于治疗或预防疾病的药物组合物,特别是神经源性疾病,作为唯一活性成分或与其他活性成分组合使用。
  • [EN] BICYCLIC UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS USEFUL FOR THE TREATMENT OF PAIN<br/>[FR] COMPOSÉS DE THIO-URÉE, GUANIDINE, CYNOGUANIDINE ET D'URÉE BICYCLIQUES UTILES POUR LE TRAITEMENT DE LA DOULEUR
    申请人:ARRAY BIOPHARMA INC
    公开号:WO2014078454A1
    公开(公告)日:2014-05-22
    Compounds of Formula I: or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C and X are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis and pelvic pain syndrome.
    公式I的化合物:或立体异构体、互变异构体、或药用可接受的盐、溶剂化物或前药,其中环A、环C和X如本文定义,是TrkA激酶的抑制剂,可用于治疗可以用TrkA激酶抑制剂治疗的疾病,如疼痛、癌症、炎症/炎症性疾病、神经退行性疾病、某些传染病、舍格伦综合症、子宫内膜异位症、糖尿病周围神经病、前列腺炎和盆腔疼痛综合症。
查看更多